ASLAN Firms Up IPO Plans As Lead Asset Progresses

Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering, which is now expected to take place in Taiwan mid May with the newly listed shares set to begin trading in early June.

Cancer cell

The Singapore-based, oncology-focused venture Aslan Pharmaceuticals Pte. Ltd., which is developing a pipeline of assets for Asia-prevalent tumor types, will float on the Taipei Exchange (TPEx) after holding an auction for the planned IPO in the middle of May.

KGI Securities is the lead underwriter for the offering, under which ASLAN expects to have paid in capital of TWD1,157m...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer